Genus plc (LON:GNS – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 2,415.33 and traded as high as GBX 2,420. Genus shares last traded at GBX 2,320, with a volume of 76,231 shares traded.
Analysts Set New Price Targets
Separately, Berenberg Bank reissued a “buy” rating and set a GBX 3,350 price target on shares of Genus in a research report on Tuesday, July 14th. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of GBX 3,216.67.
Check Out Our Latest Report on Genus
Genus Price Performance
Insider Buying and Selling
In other news, insider Celia Baxter purchased 2,336 shares of the stock in a transaction dated Friday, June 26th. The shares were purchased at an average cost of GBX 2,140 per share, with a total value of £49,990.40. Company insiders own 0.71% of the company’s stock.
Genus Company Profile
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands.
See Also
- Five stocks we like better than Genus
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.
